Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | MB | P02144 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4764114 | 0.82 | SRC (0.42) | SRCPDE3BPDE3AMB | |
| SCHEMBL29319840 | 0.81 | SRC (0.53) | SRCPDE3BPDE3AMBHPGD | |
| SCHEMBL22061405 | 0.78 | SRC (0.46) | SRCPDE3BPDE3A | |
| SCHEMBL18103980 | 0.72 | SRC (1.00) | SRCPDE3BPDE3AMBHPGD | |
| SCHEMBL12382071 | 0.71 | SRC (0.46) | SRCPDE3BPDE3AMBHPGD | |
| SCHEMBL13424558 | 0.68 | MEN1 (0.42) | SRCPDE3BPDE3A | |
| SCHEMBL25326789 | 0.67 | CRBN (0.44) | SRC | |
| SCHEMBL4044760 | 0.65 | PDE3B (0.48) | SRCPDE3BPDE3AAHR | |
| SCHEMBL21372009 | 0.64 | SRC (0.40) | SRCPDE3BPDE3AMB | |
| SCHEMBL17926499 | 0.64 | SRC (0.43) | SRCCMA1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | claimed |
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2011-09-08 | — | — | US | claimed |
| US-9688699-B2 | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-27 | — | — | US | disclosed |
| EP-3107920-A1 | 3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-28 | — | — | EP | disclosed |
| EP-2373317-B1 | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases | MERCK SHARP & DOHME (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160347770-A1 | 3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-01 | — | — | US | disclosed |
| WO-2015124544-A1 | 3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-27 | — | — | WO | disclosed |
| US-8741910-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2594270-A2 | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) | BIP Patents (DE) | 2013-05-22 | — | — | EP | disclosed |
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE2A, GUCY1A2, PDE3A | SRC 3162/4885PDE3B 4/4885PDE3A 3/4885 |
| US-20160347770-A1 | 3-(PYRIMIDINE-2-YL)IMIDAZO[1,2-A]PYRIDINES | TPMT, PNPO, PDXK | SRC 2720/4885PDE3B 277/4885PDE3A 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.